Investigating how a protein-recycling complex affects treatment resistance in small cell lung cancer.
Official title: Understanding the molecular mechanism of a protein-recycling complex in small cell lung cancer treatment resistance.
Funded at University Health Network · NIH-10684226 · Data updated 2026-11-12
This study is looking into why some people with small cell lung cancer stop responding to treatments that initially worked well for them, and it's trying to find new ways to improve those treatments by understanding the underlying causes of this resistance.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University Health Network NIH-funded |
| Lab location | 1 site (Toronto, Canada) |
| Project start | September 25, 2020 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $276,338 |
| NIH project number | 5U01CA253383-04 |
| Project ID | NIH-10684226 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with small cell lung cancer, particularly those who have experienced treatment resistance.
✕Less likely to help
Patients with small cell lung cancer who have not undergone treatment or those with non-small cell lung cancer may not benefit from this research.
What this research studies
This research focuses on understanding why small cell lung cancer (SCLC) patients often experience treatment resistance after initially responding well to therapies. The team is exploring the molecular mechanisms behind this resistance, particularly looking at the role of specific proteins and genetic factors. By using advanced techniques like CRISPR to identify resistance mechanisms, the researchers aim to find new therapeutic targets that could improve treatment outcomes for patients. The ultimate goal is to develop novel therapies that can overcome resistance and enhance the effectiveness of existing treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for small cell lung cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Other research has shown promising results in understanding treatment resistance mechanisms in various cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University Health Network
Toronto, Canada Active
Researchers
- Principal investigator: Lok, Benjamin H — University Health Network
- Study coordinator: Lok, Benjamin H
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.